ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1850

First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses

Rufei Lu1, Tayte Stephens2, Carla Guthridge1, Miles Smith1, Joseph Kheir1, Cristina Arriens1, Joan Merrill3, Marci Beel4, Susan Macwana1, Wade DeJager5, Nicholas Domingez1, Teresa Aberle1, Joel Guthridge1 and Judith James1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Science Center, Oklahoma City, OK, 3Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, 4Oklahoma Medical Research Foun, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, Biomarkers, proteomics, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1830–1854) Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are autoimmune diseases with overlapping yet distinct immunopathologies. Proteomic profiling of soluble plasma factors can reveal disease- and ancestry-specific immune dysregulation. Using RA as a disease control, we investigated ancestry-specific plasma proteomic signatures in SLE to elucidate unique pathways contributing to disease pathogenesis.

Methods: Serum samples from 90 female participants (SLE=30, RA=30, healthy controls=30) stratified by ancestry-Black, First American, and White were analyzed using the Olink Explore HT assay, quantifying over 5,000 proteins. Differential expression and pathway enrichment analyses were performed with false discovery rate correction (FDR < 0.05) to identify ancestry- and disease-specific proteomic alterations.

Results: Proteomic profiles distinctly separated SLE, RA, and healthy controls, with notable ancestry-associated differences (Figure). In SLE, all ancestries demonstrated increased lipid and vesicle-mediated transport pathways; however, First American patients uniquely exhibited lipid metabolic dysfunction. Black patients showed increased myeloid activity, including neutrophil degranulation and migration pathways. White patients displayed dysregulated protein degradation and nucleotide modification pathways, particularly involving nuclear proteins and SUMOylation. Notably, First American SLE patients had significantly elevated B-cell activation pathways, consistent with heightened interferon hypersensitivity and cellular frequency data. Using RA as a disease control, we observed that Black RA patients had pronounced upregulation of vesicle-mediated transport pathways compared to SLE. Additionally, White RA patients showed downregulation of connective tissue-related pathways and First American RA patients exhibited neuronal and vascular system pathway alterations. Across diseases, Black patients demonstrated predominant dysregulation of innate immune pathways, whereas White and First American patients showed more adaptive immune system involvement.

Conclusion: Ancestry shapes plasma proteomic landscapes in SLE and RA, with distinct immune and metabolic pathways differences. The use of RA as a disease control underscores unique SLE-specific proteomic signatures, particularly in lipid metabolism and B-cell activation among First American patients and myeloid-driven inflammation in Black patients. These results emphasize the importance of integrating ancestry and disease context in proteomic analyses to inform personalized therapeutic strategies in autoimmune diseases.

Supporting image 1. A, Heatmap of top predictors revealing distinct soluble proteomic profiles among different ancestries between rheumatic disease and healthy controls. B, UMAPs based on Olink Explore HT Assay highlighting distinct soluble proteomics between two rheumatic diseases (RA and SLE) and healthy controls. C, Volcano plots showing the differentially detected proteins (DEP) between RA and SLE and healthy controls in different ancestries. D, Heatmaps of gene set enrichment analyses based on DEPs.


Disclosures: R. Lu: None; T. Stephens: None; C. Guthridge: None; M. Smith: None; J. Kheir: None; C. Arriens: AstraZeneca, 5, Aurinia, 6, Bristol-Myers Squibb(BMS), 1, 5, Cabaletta, 1, Health and Wellness Partners, 1, Synthekine, 1, UCB, 1; J. Merrill: AbbVie, 2, Alexion, 2, Almiral, 2, Alumis, 2, Amgen, 2, AstraZeneca, 2, 5, Aurinia, 2, Biogen, 2, BMS, 2, 5, Eli Lilly, 2, EMD Serono, 2, Equillium, 2, Genentech, 2, Gilead, 2, GSK, 2, 5, Kezar, 2, Merck, 2, Novartis, 2, Ono, 2, Remegen, 2, Sanofi, 2, Takeda, 2, Tenent, 2, UCB, 2, Veloxis, 2, Zenas, 2; M. Beel: None; S. Macwana: None; W. DeJager: None; N. Domingez: None; T. Aberle: None; J. Guthridge: None; J. James: GlaxoSmithKlein(GSK), 2, Progentec, 5.

To cite this abstract in AMA style:

Lu R, Stephens T, Guthridge C, Smith M, Kheir J, Arriens C, Merrill J, Beel M, Macwana S, DeJager W, Domingez N, Aberle T, Guthridge J, James J. First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/first-american-sle-patients-demonstrate-enhanced-lipid-metabolism-and-b-cell-activation-by-high-content-proteomic-analyses/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/first-american-sle-patients-demonstrate-enhanced-lipid-metabolism-and-b-cell-activation-by-high-content-proteomic-analyses/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology